Company intelligence / Profile preview

DiamPark

Paris, Île-de-France, Francediampark.io ↗

Ownership: Private
Employees: ~20
Development stage: Other

Overview

DiamPark has developed a suite of digital tools for the diagnosis, monitoring, and therapeutic support of patients with Parkinson’s disease. Their solutions include real-time symptom tracking, medication adherence support, therapeutic education programs, and data-driven tools to evaluate treatment effectiveness. As of 2023, they are undertaking several clinical trials to validate new neuro markers and seeking reimbursement approval from French health authorities

Therapeutic areas: Neurology
Modalities: Digital toolSoftware platformTherapeutic education program
Industry: Digital Health Medical Devices

Partnerships

Not explicitly listed; company mentions strong ecosystem ties including patient committees and scientific councils but no named pharma/biotech partners as of June 2025

Beyond the preview

Go deeper on DiamPark.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DiamPark.

Explore the full profile